Capital International Sarl Decreases Position in Illumina, Inc. $ILMN

Capital International Sarl cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.0% during the fourth quarter, HoldingsChannel reports. The firm owned 105,069 shares of the life sciences company’s stock after selling 15,683 shares during the quarter. Capital International Sarl’s holdings in Illumina were worth $13,781,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new stake in Illumina during the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina during the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC raised its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the fourth quarter valued at approximately $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the transaction, the insider directly owned 21,568 shares in the company, valued at approximately $3,450,880. This trade represents a 2.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,002,371 shares of company stock worth $155,472,900 in the last ninety days. 2.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ILMN shares. Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. Canaccord Genuity Group cut their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $138.38.

Illumina Trading Down 3.4%

ILMN opened at $162.32 on Friday. The stock has a market cap of $24.56 billion, a price-to-earnings ratio of 29.51, a P/E/G ratio of 3.04 and a beta of 1.50. The stock’s 50 day moving average price is $137.75 and its 200-day moving average price is $133.57. Illumina, Inc. has a one year low of $82.44 and a one year high of $177.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.97 earnings per share. Illumina’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.